Stress oxidative in schizophrenia;Stres oksydacyjny w schizofrenii

Polski Merkuriusz Lekarski

Volumn 23, Issue 133, 2007, Pages 74-77

  Tylec, Aneta ^a   Jarza̧b, Agata ^a   Stryjecka Zimmer, Marta ^a   Wójcicka, Anna ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

CAT; GPx; MDA; Schizophrenia; SOD; Stress oxidative

Indexed keywords

ANTIOXIDANT; CATALASE; FREE RADICAL; GLUTATHIONE PEROXIDASE; MEMBRANE LIPID; NEUROPROTECTIVE AGENT; PHOSPHOLIPID; SUPEROXIDE DISMUTASE;

ARTICLE; BRAIN LEVEL; DRUG EFFECT; HUMAN; LIPID PEROXIDATION; METABOLISM; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOPHYSIOLOGY; SCHIZOPHRENIA;

ANTIOXIDANTS; BRAIN CHEMISTRY; CATALASE; FREE RADICALS; GLUTATHIONE PEROXIDASE; HUMANS; LIPID PEROXIDATION; MEMBRANE LIPIDS; NEUROPROTECTIVE AGENTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PHOSPHOLIPIDS; SCHIZOPHRENIA; SUPEROXIDE DISMUTASE;

EID: 34547787755     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Abdalla D., Monteiro H., Oliveira J. i wsp.: Activities of superoxide dismutase and glutathione peroxidase in schizophrenic and panic-depressive patients. Clin. Chem., 1986, 32, 805-807.
2. Akyol O., Herken H., Uz E. i wsp.: The indices of endogenous oxidative and antioxidative processes in plasma from schizophrenic patients. The possible role of oxidant/antioxidant imbalance. Prog. Neuro-psychopharmacol. Biol. Psychiatry, 2002, 26, 995-1005.
3. Alexander M., Ponizovsky M., Barshtein G. i wsp.: Biochemical Alterations of Erythrocytes as an Indicator of Mental Disorders: An Overview Harv. Rev. Psychiatry, 2003, 11, 317-332.
4. Altuntas I., Aksoy H., Coskun I. i wsp.: Erythrocyte superoxide dismutase and glutathione peroxidase activities, and reduced glutathione levels in schizophrenic patients. Clin. Chem. Lab. Med., 2000, 38, 1277-1281.
5. Bartosz G.: Druga twarz tlenu. Wydawnictwo Naukowe PWN, Warszawa 2003.
6. Buckman T., Kling A., Sutphin M. i wsp.: Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res., 1990, 31, 1-14.
7. Carter J.: Schizophrenia susceptibility genes converge on interlinked pathways related to glutamatergic transmission and long-term potentiation, oxidative stress and oligodendrocyte viability. Schizophrenia Research, 2006, 86, 1-14.
8. Dietrich-Muszalska A.: Wpływ dzialania haloperidolu na peroksydacjȩ lipidów w ludzkich płytkach krwi i osoczu w badaniach in vitro. Psych, i Psychol. Klin., 2004, 4 (3), 150-156.
9. Dietrich-Muszalska A., Olas B., Rabe-Jabłńska J.: Oxidative stress in blood platelets from schizophrenic patients. Platelets, 2005, 16(7), 386-391.
10. Fendri C., Mechri A., Khiari G., Othman A., Kerkeni A., Gaha L.: Oxidative stress involvement in schizophrenia pathophysiology: areview. Encephale, 2006, 32 (2), 244-252.
11. Gatecki P., Pietras T., Florkowski A.: Procesy pro- i antyoksydacyjne u osob chorych na schizofreniȩ z objawami póżnych dyskinez. Psychiatria Pol. 2005, 6, 1131-1141.
12. Galecki P., Florkowski A., Zboralski K.: Stres oksydacyjny a schizofrenia. Valetudinaria 2005, 10 (1), 48-51.
13. Gatecki P., Pietras T., Szmeraj J. i wsp.: Funkcjonalny polimorfizm genu manganowej dysmutazy ponadtlenkowej (MnSOD) u chorych na schizofreniȩ w polskiej populacji. Pol. Merk. Lek., 2006, 117, 329-332.
14. Herken H., Uz E., Ozyurt H. i wsp.: Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol. Psychiatry, 2001, 6, 66-73.
15. Horrobin D., Manku M., Hillman H. i wsp.: Fatty acid levels in the brains of schizophrenics and normal controls. Biol. Psychiatry, 1991, 30, 795-805.
16. Keshavan M., Mallinger A., Pettegrew J. i wsp.: Erythrocyte membrane phospholipids in psychotic patients. Psychiatry Res., 1993, 49, 89-95.
17. Khan N., Das I.: Oxidative stress and superoxide dismutase activity in schizophrenia. Biochem. Soc. Trans., 1997, 25, 418S.
18. Khan M., Evans D., Gunna V. i wsp.: Reduced erythrocyte membrane essential fatty acids and increased lipid peroxides in schizophrenia at the never-mediated first-episode of psychosis and after years of treatment with antipsychotics. Schizophr. Res., 2002, 58, 1-10.
19. Kropp S., Kern V., Lange K. i wsp.: Oxidative Stress During Treatment With First and Second-Generation Antipsychotics. J. Neuropsych and Clin. Neurosc., 2005, 17, 227-231.
20. Lohr J., Underhill S., Moir S. i wsp.: Increased indices of free radical activity in the cerebrospinal fluid of patients with tardive dyskinesia. Biol. Psychiatry, 1990, 28, 535-539.
21. Lohr J., Kuczenski R., Niculescu A.: Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003, 17, 47-62.
22. Mahadik S., Mukherjee S.: Free radical pathology and antioxidant defense in schizophrenia: a review. Schizophr. Res., 1996, 19, 1-17.
23. Mahadik S., Mukherjee S., Correnti E. i wsp.: Elevated plasma lipid peroxides at the onset of nonaffective psychosis. Biol. Psychiatry, 1998, 43, 674-679.
24. Mahadik S., Sitasawad S., Mulchandani M.: Membrane peroxidation and the neuropathology of schizophrenia. In: Peet M., Glen I., Horrobin D.F. (eds.): Phospholipid spectrum disorder in psychiatry. Carnforth, England, Marius, 1999, 99-112.
25. McConnell E., Bittelmeyer A., Raess B.: Irreversible inhibition of plasma membrane (Ca 2+ + Mg 2+) ATPase and CA2+ transport by 4-OH-2, 3-trans-nonenal. Arch. Biochem. Biophys., 1999, 361, 252-256.
26. McCreadie R., Macdonald E., Wiles D. i wsp.: The Nithsdale Schizophrenia Surveys XIV: plasma lipid peroxide and serum vitamin E levels in patients with and Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry, 1995, 62, 878-883.
27. Miller R., Rice C., Davies M. i wsp.: A novel method for measuring antioxidant capacity and its application to monitoring the antioxidant status. Clin. Sci., 1993, 84, 407-412.
28. Mukherjee S., Mahadik S., Scheefer R. i wsp.: Impaired antioxidant defense at the onset of psychosis. Schizophr. Res., 1996, 19, 19-26.
29. Murray R., Granner D., Mayes P. i wsp.: Biochemia Harpera. PZWL, Warszawa 2004.
30. Nagy J., Demaster E., Wittmann I. i wsp.: Induction of endothelial cell injury by cigarette smoke. Endothelium, 1997, 5, 251-263.
31. Ponizovsky A., Barshtein G., Bergelson L.: Biochemical Alterations of Erythrocytes as an Indicator of Mental Disorders: An Overview Harv. Rev. Psych., 2003, 6, 317-332.
32. Prabakaran S., Swatton J., Ryan M. i wsp.: Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol. Psychiatry, 2004, 9, 684-697.
33. Prabakaran S., Wengenroth M., Lockstone H. i wsp.: 2-D DIGE Analysis of Liver and Red Blood Cells Provides Further Evidence for Oxidative Stress in schizophrenia. J. Proteome Res., 2007, 6 (1), 141-149.
34. Pratico D., Delanty N.: Oxidative injury in diseases of the central nervous system : focus on Alzhaimer's disease. Am. J. Med. 2000, 109, 577-585.
35. Ranjekar P., Hinge A., Hegde M. i wsp.: Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res., 2003, 121, 109-122.
36. Reddy R., Sahebarao M., Mukherjee S. i wsp.: Enzymes of the antioxidant defense system in chronic schizophrenic patients. Biol. Psychiatry, 1991, 30, 409-412.
37. Reddy R., Yao J.: Free radical pathology in schizophrenia: a review. Prostaglandins Leukot. Essent. Fat. Acids, 1996, 55, 33-43.
38. Rusznak C., Sapsford R., Devalia J. i wsp.: Smoke Potentiates House Dust Mite Allergen-Induced Increase in the Permeability of Human Bronchial Epithelial Cells In Vitro. Am. J. Respir. Cell. Mol. Biol., 1999, 20, 1238-1250.
39. Sayre L., Smith M., Perry G.: Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem., 2001, 8, 721-738.
40. Tsai G., Goff D., Chang R. i wsp.: Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. Am. J. Psychiatry, 1998, 155, 1207-1213.
41. Vaiva G., Thomas P., Leroux J. i wsp.: Erythrocyte superoxide dismutase (eSOD) determination in positive moments of psychosis. Therapie, 1994, 49, 343-348.
42. Wayner D., Burton G., Ingolg K. i wsp.: The relative contributions of witamin E, urate, ascorbate and proteins to the total peroxyl radical-trapping antioxidant activity of human blood plasma. Biochim. Biophys. Acta, 1987, 924, 408-419.
43. Yamada I., Kanba S., Anamizu S. i wsp.: Low superoxide dismutase actvity in schizophrenic patients with tardive dyskinesia. Psychol. Med., 1997, 27, 1223-1225.
44. Yao J., Reddy R., van Kammen D., Kelley M.: Superoxide dismutase and negative symptoms in schizophrenia. Biol. Psychiatry, 1998, 43, 123S-124S.
45. Yao J., Reddy R., van Kammen D.: Human plasma glutathione peroxidase and symptom severity in schizophrenia. Biol. Psychiatry, 1999, 45, 1512-1515.
46. Yao J.: Reci blood cell and platelet fatty acid metabolism in schizophrenia. In: Peet M., Glen I., Horrobin D.F. (eds.): Phospholipid spectrum disorder in psychiatry. Carnforth, England, Marius, 1999, 57-71.
47. Yao J., Reddy R., van Kammen D.: Abnormal agerelated changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res., 2000, 97, 137-151.
48. Yao J., Reddy R., van Kammen D.: Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs, 2001, 15, 287-310.
49. Yao J., Leonardd S., Reddya R.: Altered glutathione redox state in schizophrenia. Disease Markers, 2006, 22, 83-93.
50. Yasuno K., Ando S., Misumi S. i wsp.: Synergistic association of mitochondrial uncoupling protein (UCP) genes with schizofrenia. Am. J. Med. Genet. B. Neuropsychiatr. Genet., 2006, 25.
51. Zdolsek J., Stevensson L.: Effected of reactive oxygen species on lysosomal membrane integrity. A study on lysosomal fraction. Virchows Arcg. B Cell. Pathol. Incl. Mol. Pathol., 1993, 64, 401-406.
52. Zhang X., Zhou D., Zhang P. i wsp.: A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J. Clin. Psychiatry, 2001, 62, 878-883.
53. Zhang X., Zhou D., Cao L. i wsp.: The effect of risperidone treatment on superoxide dismutase in schizophrenia. J. Clin. Psychopharm., 2003, 23, 128-131.
54. Zhang X., Zhou D., Cao L. i wsp.: Elevated blood superoxide dismutase in neuroleptic-free schizophrenia: association with positive symptoms. Psychiatry Res., 2003, 117, 85-88.
55. Zhang X., Zhou D., Cao L. i wsp.: Blood superoxide dismutase level in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr. Res., 2003, 62, 245-250.
56. Zhang X., Tan Y., Cao L. i wsp.: Antioxidant enzymes and lipid peroxidation in different forms of schizophrenia treated with typical and atypical antipsychotics. Schizophrenia Research, 2006, 81, 291-300.